In case study 3, we applied VIBE to analyze DEGs found by other tools, showing the expression of these genes and gene signatures across outcome groups and TCGA indications, thereby identifying TYRP1 as a potential target for melanoma patients who have progressed on nivolumab. Here, TYRP1 is linked to melanoma.